The new drug ‘Leqembi (lecanemab-irmb),’ which reduces the rate of disease progression and slows cognitive decline from Alzheimer's disease, has received marketing authorization in Korea.

The Ministry of Food and Drug Safety (MFDS) announced on Thursday that it has approved Eisai Korea’s Leqembi, a new drug for Alzheimer's disease.

Leqembi was approved as a treatment to slow the progression of mild cognitive impairment (MCI) and mild dementia due to Alzheimer's disease.’

The drug has been proven to reduce the rate of disease progression and slow cognitive decline by selectively binding to amyloid beta (Aβ) aggregates, which are a known cause of Alzheimer's disease.

Lee, Hye-Kyung(hgrace7@dailypharm.com)